ESMO Congress 2025

Join Tempus at ESMO Congress 2025 to explore our latest clinical research and newest product offerings. Experience live demos of our AI-powered technologies that simplify test ordering, deliver key patient insights, and empower researchers with tools to analyze real-world data—all to support more precise, personalized cancer care.

Schedule a meeting with us

Tempus Evening Reception

Join us on the water at Patio Restaurant in Berlin to discover Tempus' groundbreaking work in precision medicine. Network with peers over food and light refreshments on a riverside boat with views of the Spree. RSVP is required.

Saturday, 18 October 2025
19:00-21:00

Patio Restaurant
Ecke, Kirchstraße, Helgoländer Ufer 13 a,
10557 Berlin, Germany

RSVP here

AI-Enabled Technologies
Research Highlights

AI-Enabled Technologies

October 17, 2025 - October 20, 2025

Time
10:00 - 18:30

Location
Booth #1001

Experience live demos of our newest technologies for providers, biopharma, and research partners.

Stop by our booth to discover how we are leveraging AI-enabled technologies to advance precision oncology.

Tempus Lens

Quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets. Explore unstructured clinical data and extract nuanced insights. With Lens, the power of Tempus data is at your fingertips.

Tempus Hub

Streamline ordering and get quick access to patient information through our secure online platform. Place orders tailored to your patient’s diagnosis with one click, view comprehensive smart reports, and review patient medical history—all in one place.

Tempus One

Get real-time answers and uncover patient insights with our generative AI assistant built for healthcare providers and researchers. Just ask a question to access data-driven responses instantly.

Research Highlights

Poster Highlights

Authors
Deepak Kilari (Medical College of Wisconsin), et al.

Presentation Number
2452P

Impact of tumor suppressor gene (TSG) alteration (alt) burden on outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Authors
Maru J. Fidler (Rush University Medical Center), et al.

Presentation Number
1919P

Unveiling Integrin Beta-6 (IB6): Real-World Data From the IB6 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Study

Authors
Nakul Shah (MD Anderson Cancer Center), et al.

Presentation Number
94P

The association between tumor immunogenomic features and first-line (1L) therapeutic outcomes in advanced biliary tract cancer (BTC)

Authors
Jay M. Lee (UCLA Health Thoracic Surgery), et al.

Presentation Number
1920P

ImmunoDriver-2: CD8 T cell and PD-L1 levels associate with first-line (1L) overall survival (OS) in immune checkpoint inhibition (ICI)-treated non-small cell lung cancer (NSCLC)

October 17, 2025

Oral Presentations

Time
17:10 - 17:15

Room
Karlsruhe Auditorium - Hall 5.2

Authors
Rana R. McKay (University of California, San Diego), et al.

Presentation Number
2593MO

Impact of tumor suppressor gene (TSG) alteration (alt) burden on outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Time
16:35 - 16:40

Room
Karlsruhe Auditorium - Hall 5.2

Authors
Scott M. Haake (Vanderbilt University Medical Center), et al.

Presentation Number
2591O

Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker

Schedule a meeting with us

We'll be in touch shortly.